SEARCH:   Advanced

Blood, 27 August 2009, Vol. 114, No. 9, pp. 1729-1735. Prepublished online as a Blood First Edition Paper on June 26, 2009; DOI 10.1182/blood-2009-04-205013. This Article Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2009-04-205013v1 114/9/1729    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Google Scholar Articles by Kumar, S. Articles by Rajkumar, S. V. PubMed PubMed Citation Articles by Kumar, S. Articles by Rajkumar, S. V. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted April 10, 2009 Accepted May 27, 2009 Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide, lenalidomide or bortezomib- containing regimens Shaji Kumar*, Sergio Giralt, Edward A. Stadtmauer, Jean L. Harousseau, Antonio Palumbo, William Bensinger, Raymond L. Comenzo, Suzanne Lentzsch, Nikhil Munshi, Ruben Niesvizky, Jesus San Miguel, Heinz Ludwig, Leif Bergsagel, Joan Blade, Sagar Lonial, Kenneth C. Anderson, Patrizia Tosi, Pieter Sonneveld, Orhan Sezer, David Vesole, Michele Cavo, Hermann Einsele, Paul G. Richardson, Brian G.M. Durie, and S. Vincent Rajkumar Mayo Clinic, Rochester, MN, United States The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States University of Pennsylvania Abramson Cancer Center, Philadelphia, PA, United States Institute de Biologie, Nantes, France Universita di Torino, Azienda Ospedaliera S. Giovanni Battista, Ospedale Molinette, Torino, Italy Fred Hutchinson Cancer Research Center, Seattle, WA, United States Memorial Sloan-Kettering Cancer Center, New York, NY, United States University of Pittsburgh UMPC Cancer Pavilion, Pittsburgh, PA, United States Dana-Farber Cancer Institute, Boston, MA, United States Weill Cornell Medical College, New York, NY, United States Hospital Universitario de Salamanca, CIC, IBMCC (USAL-CSIC), Salamanca, Spain Wilhelminenspital, Wien, Vienna, Austria Hospital Clinic, IDIBAPS, Barcelona, Spain Emory University, Atlanta, GA, United States University of Bologna, Bologna, Italy Erasmus MC, Rotterdam, Netherlands University of Berlin, Berlin, Germany Loyola University, Chicago, IL, United States Institute of Hematology and Medical Oncology Seragnoli, Bologna, Italy University of Wurzburg, Wurzburg, Germany Aptium Oncology, Inc., Cedars-Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, United States * Corresponding author; email: kumar.shaji{at}mayo.edu. The past decade has witnessed a paradigm shift in the initial treatment of multiple myeloma with the introduction of novel agents such as thalidomide, lenalidomide and bortezomib, leading to improved outcomes. High dose therapy and autologous stem cell transplantation remains an important therapeutic option for patients with multiple myeloma eligible for the procedure. Prior to the advent of the novel agents, patients underwent stem cell collection prior to significant alkylating agent exposure, given their potential deleterious effect on stem cell collection. With increasing use of the novel agents in the upfront setting, several reports have emerged raising concerns about their impact on the ability to collect stem cells. An expert panel of the International Myeloma Working Group was convened to examine the implications of these therapies on stem collection in patients with myeloma and to develop recommendations for addressing these issues. Here we summarize the currently available data and present our perspective on the problem and potential options to overcome this problem. Specifically, we recommend early mobilization of stem cells, preferable with in the first 4 cycles of initial therapy, in patients treated with novel agents and encourage participation in clinical trials evaluating novel approaches to stem cell mobilization. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. K. Kumar, J. R. Mikhael, F. K. Buadi, D. Dingli, A. Dispenzieri, R. Fonseca, M. A. Gertz, P. R. Greipp, S. R. Hayman, R. A. Kyle, et al. Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines Mayo Clin. Proc., December 1, 2009; 84(12): 1095 - 1110. [Abstract] [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020